CMS said in its latest Medicare Drug Price Negotiation Program guidance it still working on a process to allow manufacturers to avoid providing a 340B price and a negotiated fair price for the same drug.

340B Issues Remain Unresolved in Latest CMS Medicare Drug Price Negotiation Guidance

July 7, 2023 Rich Daly, Editor in Chief Views

The latest guidance to implement first-time drug price negotiation under Medicare said federal officials still are looking for a process [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

340B Issues Remain Unresolved in Latest CMS Medicare Drug Price Negotiation Guidance

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Rich Daly

340B Issues Remain Unresolved in Latest CMS Medicare Drug Price Negotiation Guidance

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Rich Daly

Site Footer Live